<DOC>
	<DOCNO>NCT01700946</DOCNO>
	<brief_summary>The overall objective protocol improve cure rate relapse precursor B-cell acute lymphoblastic leukemia ( ALL ) lymphoblastic lymphoma . This phase II trial study risk-directed therapy B-lymphoblastic leukemia lymphoma first relapse . Standard risk ( SR ) high risk ( HR ) participant receive different therapy . Treatment consist chemotherapy SR participant , chemotherapy follow hematopoietic stem cell transplant ( HSCT ) HR first relapse . Induction therapy consist three block chemotherapy . The first block novel immunotherapy regimen include chemotherapy , rituximab infusion haploidentical natural killer ( NK ) cell . SR participant continue receive chemotherapy total duration approximately 2 year . HR participant candidate HSCT proceed transplant suitable donor find minimal residual disease ( MRD ) negative .</brief_summary>
	<brief_title>Therapy Pediatric Relapsed Refractory Precursor B-Cell Acute Lymphoblastic Leukemia Lymphoma</brief_title>
	<detailed_description>Primary objective - To estimate 3-year survival rate participant first relapse primary refractory precursor B-cell ALL lymphoblastic lymphoma treat risk-directed therapy . Secondary objective - To determine minimal residual disease ( MRD ) level end remission induction therapy participant relapse precursor B-cell ALL compare result protocol ALLR17 - To estimate level CD20 expression baseline , treatment dexamethasone-containing chemotherapy follow rituximab treatment Block 1 remission induction therapy relapse precursor B-cell ALL . STUDY DESCRIPTION : The general treatment plan consist chemotherapy standard-risk participant chemotherapy follow HSCT high risk participant first relapse B-precursor ALL lymphoblastic lymphoma . Remission induction participant consist three block therapy , wherein first block novel immunotherapy regimen include cytotoxic chemotherapy , rituximab infusion haploidentical natural killer ( NK ) cell . Standard-risk patient continue receive chemotherapy total duration approximately 2 year . High-risk patient candidate HSCT proceed transplant suitable donor find patient achieves negative MRD . Participants assign standard arm experience late relapse ( &gt; = 6 month completion frontline therapy ) AND maximum residual disease ( MRD ) &lt; 0.01 % end Block II remission induction therapy . Provisional standard risk participant ( i.e. , late relapse ) re-assigned high risk MRD &gt; = 0.01 % end Block II . participant lymphoma must complete remission end Block III . High risk participant meet one follow criterion : - Early relapse ( therapy &lt; 6 month completion frontline therapy ) , OR - Any relapse hematopoietic stem cell transplant , OR - MRD &gt; = 0.01 % end Block II remission induction therapy , OR - Re-emergence MRD time attain negative MRD clinical trial . Natural killer ( NK ) cell collection : Donors meet eligibility criterion undergo apheresis . The cell obtain purified CD56+ cell utilize CliniMACS selection system . The NK cell product undergo quality control test follow standard operating procedure St. Jude Human Applications Laboratory . OUTLINE ( STANDARD RISK ) : REMISSION INDUCTION : BLOCK I : Patients receive dexamethasone orally ( PO ) intravenously ( IV ) thrice daily ( TID ) day 1-8 21-28 ; vincristine sulfate IV day 1 , 21 , 28 , 35 ; rituximab IV day 4 , 13 , 20 , 27 ; clofarabine , cyclophosphamide , etoposide IV day 6-10 ; aldesleukin subcutaneously ( SC ) every day ( QOD ) day 11-19 ; pegaspargase IV day 21 , 28 , 35 . Patients also undergo natural killer ( NK ) cell infusion day 12 . Patients may receive triple intrathecal therapy comprise methotrexate , therapeutic hydrocortisone , cytarabine day 1 , 5 , 8 , 11 , 21 , 28 . Patients continue Block II count recovery . BLOCK II : Patients receive methotrexate IV 24 hour day 1 8 mercaptopurine PO day 1-21 . Patients also receive triple intrathecal therapy day 1 . High-risk patient negative MRD continue transplantation . All patient positive MRD continue Block III count recovery . BLOCK III : Patients receive cytarabine IV 2 hour twice daily ( BID ) day 1-4 mitoxantrone hydrochloride IV 1 hour day 3-5 . Patients also receive triple intrathecal therapy day 7 . INTERIM CONTINUATION ( patient unable tolerate dose intensive chemotherapy ) : Patients receive etoposide cyclophosphamide IV day 1 , methotrexate IV day 8 , mercaptopurine PO day 8-14 , teniposide cytarabine IV day 15 , dexamethasone PO TID day 22-26 , vinblastine IV day 22 . RE-INDUCTION THERAPY : Patients receive clofarabine , cyclophosphamide , etoposide IV day 1-5 ; dexamethasone PO day 1-6 ; pegaspargase vincristine sulfate IV day 6 , 13 , 20.Patients may also receive triple intrathecal therapy day 1 15 . Patients continue continuation treatment count recovery . CONTINUATION TREATMENT : Patients receive methotrexate IV 2 hour day 1 mercaptopurine PO day 1-7 week 1 , 2 , 5 , 6 ; teniposide cytarabine IV day 1 week 3 7 ; vincristine sulfate IV day 1 week 4 ; dexamethasone PO TID day 1-5 week 4 8 ; vinblastine IV day 1 week 8 . Treatment repeat every 8 week 10 course absence disease progression unacceptable toxicity . Patients may also receive triple intrathecal therapy day 1 week 1 course day 1 week 5 course 6-10 . OUTLINE : GROUP 2 ( high risk define participant meet standard risk criterion note ) : Patients receive Remission Induction ( Blocks I , II , III ) treatment describe Group 1 . Patients undergo allogeneic hematopoietic stem cell transplantation ( HSCT ) soon negative MRD . Patients negative MRD may continue chemotherapy suitable donor find . After completion study treatment , patient follow every 4 month 1 year , every 6 month 1 year , yearly 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA : Must relapse refractory precursor Bcell acute lymphoblastic leukemia acute lymphoblastic lymphoma . Participants leukemia must meet one follow : 1 . In first hematologic relapse , define reappearance ( patient previously achieve remission ) leukemia blast bone marrow , OR 2 . Refractory one two course frontline induction therapy ( ≥ 5 % blast bone marrow confirm flow cytometric analysis ) . Participant lymphoma must meet one follow : 1 . In first relapse , OR 2 . Refractory one two course frontline induction therapy measurable disease Should flow cytometric analyse suggest relapse ( reappearance similar immunophenotype original leukemia ) presence &lt; 5 % blast morphologically , repeat bone marrow test recommend confirm relapse . Molecular genetic relapse characterize reappearance cytogenetic molecular abnormality . Early relapse define relapse therapy &lt; 6 month completion frontline therapy . Late relapse define relapse occur ≥ 6 month completion frontline therapy . Participant 's age &lt; 22 year time enrollment ( e.g . participant eligible 22nd birthday ) . Prior therapy : 1 . There wait period participant relapse receive frontline therapy free side effect attributable therapy . 2 . Emergent radiation therapy , one dose intrathecal chemotherapy , 7 day steroid treatment relapse permit start treatment participant relapse completion frontline therapy . 3 . At least 90 day elapse since bone marrow transplant participant immune suppression minimum 2 week , applicable . Participants ALL NHL transplant first remission eligible study . Organ function requirement Hepatic : Total bilirubin ≤ upper limit normal ( ULN ) age , total bilirubin &gt; ULN , direct bilirubin &lt; 1.4 mg/dl Cardiac : Shortening fraction &gt; 28 % Renal : Glomerular filtration rate &gt; 50cc/min/1.73 m^2 , OR maximum serum creatinine ( SC ) base age follow : If age 1 2 year , maximum SC 0.6 mg/dL If age 2 6 year , maximum SC 0.8 mg/dL If age 6 10 year , maximum SC 1 mg/dL If age 10 &lt; 13 year , maximum SC 1 mg/dL If age 13 16 year , maximum SC 1.5 mg/dL male 1.4 mg/dL female If age &gt; 16 year , maximum SC 1.7 mg/dL male 1.4 mg/dL female EXCLUSION CRITERIA : Leukemia participant age 1 5 year induction failure AND favorable cytogenetics ( i.e. , hyperdiploidy define DNA index ≥1.16 modal chromosome number ≥51 , ETV6RUNXI ) . Hepatitis B HIV infection . Pregnant breastfeed Inability unwillingness research participant legal guardian/representative give write informed consent . INCLUSION CRITERIA FOR NK CELL DONORS : Donor least 18 year age . Donor family member .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Non-Hodgkins</keyword>
</DOC>